comput
vaccinolog
includ
epitop
map
antigen
select
immunogen
design
use
comput
tool
tool
facilit
silico
predict
immun
respons
biothreat
emerg
infecti
diseas
cancer
acceler
design
novel
next
gener
vaccin
deliveri
clinic
past
year
vaccinologist
bioinformat
expert
advanc
programm
base
provid
rhode
island
usa
advanc
develop
integr
toolkit
vaccin
design
call
ivax
secur
useraccess
internet
integr
set
immunoinformat
tool
compris
algorithm
score
triag
candid
antigen
select
immunogen
conserv
cell
epitop
reengin
elimin
regulatori
cell
epitop
redesign
antigen
induc
immunogen
protect
diseas
human
livestock
commerci
academ
applic
ivax
includ
identifi
immunogen
cell
epitop
develop
tcell
base
human
multiepitop
q
fever
vaccin
design
novel
influenza
vaccin
identifi
crossconserv
cell
epitop
malaria
vaccin
analyz
immun
respons
clinic
vaccin
studi
anim
vaccin
applic
date
includ
viral
infect
pig
swine
influenza
african
swine
fever
rapidfir
applic
biodefens
includ
demonstr
project
lassa
fever
q
fever
recent
infecti
diseas
outbreak
underscor
signific
vaccinedriven
prepared
integr
set
tool
avail
ivax
toolkit
stand
readi
help
vaccin
develop
deliv
genomederiv
epitopedriven
vaccin
past
year
academ
research
commerci
compani
develop
immunoinformat
tool
discov
cell
epitop
trigger
activ
immun
system
appli
tool
vaccin
design
pace
algorithm
develop
discov
epitop
design
vaccin
recent
acceler
due
renew
interest
epitopebas
vaccin
gener
introduct
immun
checkpoint
inhibitor
field
oncolog
emerg
new
pathogen
review
describ
vaccin
design
tool
develop
author
applic
epitop
discoveri
antigen
engin
immunolog
research
widerang
collabor
illustr
sever
case
studi
start
cell
epitop
discoveri
illustr
cell
epitop
relev
vaccin
safeti
efficaci
antigen
character
antigen
engin
vaccin
design
believ
cell
epitop
deserv
greater
focu
vaccin
develop
even
absenc
effect
antibodi
respons
cell
epitop
import
driver
immun
defens
pathogen
may
also
facilit
escap
immun
defens
specif
new
inform
crossconserv
pathogen
cell
epitop
human
genom
microbiom
emerg
import
implic
vaccin
design
exampl
memori
crossconserv
cell
epitop
defin
key
contributor
strength
protect
gener
vaccin
discoveri
come
light
applic
new
tool
examin
cell
epitop
role
vaccin
use
power
immunoinformat
one
newest
tool
describ
address
concept
immun
camouflag
figur
begin
observ
tcr
face
epitop
present
pathogen
contain
pattern
amino
acid
ident
cell
epitop
bind
hla
allel
highli
preval
human
proteom
hypothes
role
humanlik
cell
epitop
may
toler
pathogen
activ
selfreact
treg
suppress
immun
respons
also
observ
immun
camouflag
like
present
pathogen
capac
modifi
antigen
gener
evid
concept
also
relev
cancer
vaccin
could
improv
safeti
efficaci
vaccin
valid
immun
camouflag
hypothesi
retrospect
prospect
studi
develop
new
tool
ivax
call
janusmatrix
triag
humanlik
epitop
other
highlight
import
role
humanlik
cell
epitop
abrog
effect
vaccin
respons
furthermor
use
tool
call
optimatrix
design
immuneengin
vaccin
enhanc
immunogen
remov
humanlik
epitop
ivax
toolkit
advanc
describ
explor
hlarestrict
person
natur
immun
respons
novel
antigen
develop
figur
immun
camouflag
cell
epitop
found
sequenc
virus
bacteria
parasit
andor
human
microbiom
may
conserv
highli
preval
cell
epitop
found
selfprotein
human
genom
crossconserv
may
observ
tcr
face
peptid
bind
hla
ident
sequenc
may
enabl
pathogen
trigger
ignor
activ
toler
cell
train
selfepitop
adapt
mois
et
al
specif
tool
address
type
evalu
call
item
individu
cell
epitop
measur
epicc
epitop
content
comparison
respect
section
follow
describ
newest
ivax
tool
illustr
applic
tool
current
vaccin
develop
program
highlight
recent
collabor
relat
develop
vaccin
rang
human
anim
pathogen
comput
vaccin
design
also
known
comput
vaccinolog
encompass
epitop
map
antigen
select
immunogen
design
use
comput
tool
silico
predict
immun
respons
emerg
infecti
diseas
cancer
acceler
design
novel
next
gener
vaccin
ivax
toolkit
integr
set
immunoinformat
algorithm
develop
sinc
compris
suit
immunoinformat
algorithm
triag
candid
antigen
select
immunogen
conserv
cell
epitop
elimin
potenti
regulatori
cell
epitop
optim
antigen
immunogen
protect
diseas
aspect
toolkit
publish
see
ivax
toolkit
significantli
upgrad
new
tool
integr
valid
new
tool
publish
focu
newest
tool
provid
illustr
exampl
ivax
applic
illustr
figur
ivax
incorpor
larg
number
tool
use
sequenti
individu
manipul
inform
deriv
core
cell
epitop
map
tool
epimatrix
tool
conservatrix
epimatrix
clustim
epiassembl
algorithm
describ
great
detail
previous
newer
tool
includ
vaxcad
algorithm
creat
stringofbead
vaccin
design
minim
deleteri
junction
epitop
may
creat
process
link
one
epitop
anoth
addit
tool
integr
websit
sinc
includ
janusmatrix
special
tailor
homolog
analysi
tool
examin
pathogenhost
sequenc
similar
mhc
tcr
interfac
given
peptid
predict
potenti
crossconserv
epitop
allow
candid
sequenc
potenti
host
crossconserv
tcr
face
preferenti
exclud
vaccin
construct
item
enabl
analysi
individu
immun
respons
vaccin
antigen
accord
hla
haplotyp
latter
two
tool
also
integr
separ
pipelin
person
cancer
vaccin
design
call
ancer
licens
epivax
oncolog
investorback
spin
epivax
everi
vaccin
design
project
begin
analysi
cell
epitop
content
search
class
hla
ligand
class
ii
hla
ligand
put
epitop
perform
use
epimatrix
antigen
sequenc
obtain
databas
genbank
uniprot
input
fasta
format
theori
need
limit
number
input
sequenc
entir
host
genom
eg
mycobacterium
tuberculosi
burkholderia
mallei
pseudomallei
coxiella
burnetii
fact
analyz
perform
epimatrix
epitopemap
analysi
input
sequenc
first
pars
overlap
frame
frame
class
pars
evalu
pattern
match
known
hlabind
prefer
panel
nine
common
supertyp
class
ii
hla
allel
six
class
supertyp
allel
use
epimatrix
allel
select
rel
common
within
human
popul
rel
distinct
supertyp
hla
bind
prefer
function
equival
nearli
equival
mani
addit
famili
member
allel
taken
collect
nine
hla
class
ii
supertyp
allel
along
respect
famili
member
cover
wellov
hla
type
present
human
popul
group
six
supertyp
allel
along
respect
famili
member
cover
human
popul
group
includ
east
asian
popul
even
though
antigen
analysi
gener
perform
popul
level
mani
instanc
precis
hlabyhla
analysi
may
requir
past
figur
tool
compris
ivax
toolkit
laboratori
tool
use
valid
studi
ivax
toolkit
onlin
secur
access
toolkit
provid
individu
site
academ
commerci
user
sequenc
upload
analyz
class
class
ii
cell
epitop
use
epimatrix
search
cluster
epitop
promiscu
epitop
use
clustim
tool
conservatrix
defin
crossstrain
conserv
epitop
janusmatrix
identifi
cell
epitop
induc
anergi
activ
toler
algorithm
other
vaxcad
item
integr
secureaccess
cloudbas
toolkit
beyond
silico
analysi
phase
vaccin
design
usual
proce
vitro
vivo
valid
year
epimatrix
updat
includ
mani
hla
allel
standard
six
class
supertyp
class
ii
archetyp
class
class
ii
allel
avail
well
murin
ia
ie
haplotyp
balbc
epitop
predict
swine
sla
allel
class
class
ii
allel
avail
capac
evalu
set
hla
enabl
person
predict
make
toolkit
use
evalu
individu
subject
respons
vaccin
antigen
explor
hlaspecif
vulner
pathogen
escap
data
use
gener
epimatrix
matrixbas
predictor
describ
previous
sourc
develop
tool
includ
immun
epitop
databas
iedb
exampl
uniqu
cell
epitop
hla
ligand
elut
peptid
collect
human
hla
allel
class
matric
class
ii
matric
base
similarli
larg
dataset
start
point
appli
intern
algorithm
clean
databas
downselect
final
list
epitop
inform
matric
care
curat
highqual
binder
remov
lowqual
binder
enabl
epimatrix
perform
better
averag
tool
illustr
recent
headtohead
comparison
publish
hla
class
ligand
figur
figur
show
recent
comparison
epimatrix
score
elut
peptid
gener
publicli
avail
tool
netmhcpan
made
possibl
public
larg
set
elut
peptid
figur
show
recent
hla
bind
studi
hla
class
iirestrict
epitop
perform
epivax
publish
unpublish
addit
cell
epitop
hla
bind
valid
studi
publish
cours
grantfund
research
collabor
describ
cell
immun
respons
predict
epitop
vitro
use
human
lymphocyt
see
also
prospect
vivo
immunogen
vaccin
efficaci
studi
murin
model
see
order
select
antigen
vaccin
design
import
consid
overal
potenti
immunogen
directli
relat
cytotox
cell
ctl
helper
th
cell
epitop
content
even
though
effect
adjuv
innat
immun
system
critic
import
immunogen
danger
signal
unlik
effect
cell
epitop
activ
immun
system
react
thu
hypothes
greater
concentr
hla
ligand
put
cell
epitop
contain
antigen
like
induc
immun
respons
hypothesi
gener
support
prospect
studi
caveat
correct
total
cell
epitop
count
presenc
treg
epitop
like
import
method
perform
analysi
larg
scale
yet
extens
valid
prospect
studi
threshold
crossconserv
extens
test
whole
antigen
thu
group
prefer
evalu
antigen
put
treg
epitop
casebycas
basi
cell
epitop
concentr
express
overal
epimatrix
score
call
epimatrix
protein
score
differ
number
predict
cell
epitop
expect
random
protein
sequenc
number
put
epitop
predict
epimatrix
system
given
protein
normal
length
per
amino
acid
frontier
immunolog
wwwfrontiersinorg
averag
number
cell
epitop
contain
randomli
gener
protein
sequenc
set
zero
highli
immunogen
vaccin
antigen
score
higher
normal
scale
human
protein
gener
score
lower
randomli
gener
protein
scale
recent
perform
assess
class
ii
hla
dr
cell
epitop
content
human
protein
median
score
entir
human
proteom
found
suggest
cell
epitop
could
support
deleteri
autoimmun
activ
tend
present
lower
expect
number
median
score
secret
protein
even
lower
suggest
protein
greater
likelihood
uptak
present
apc
deimmun
word
may
evolutionarili
advantag
human
proteom
deimmun
respect
cell
epitop
content
shown
blue
figur
first
describ
concept
propos
may
advantag
selfprotein
deimmun
reduc
likelihood
autoreact
similar
figur
epimatrix
immunogen
scale
show
vaccin
antigen
human
protein
report
immunogen
nonimmunogen
antigen
alongsid
median
score
set
protein
human
genom
vaccin
antigen
sequenc
obtain
uniprot
epimatrix
immunogen
scale
set
zero
base
median
hla
dr
score
set
random
protein
sequenc
normal
hla
score
enabl
direct
comparison
median
hla
dr
score
candid
antigen
exampl
candid
vaccin
antigen
would
prefer
candid
vaccin
antigen
b
inclus
vaccin
design
elicit
helper
immun
respons
drive
humor
respons
propens
observ
human
pathogen
normal
epimatrix
protein
score
given
protein
good
proxi
immunogen
howev
region
immunogen
also
determin
immunogen
potenti
protein
cell
epitop
observ
cluster
region
protein
sequenc
cell
epitop
cluster
defin
use
clustim
clusterfind
algorithm
ivax
cluster
rang
nine
roughli
amino
acid
length
contain
anywher
four
forti
hla
bind
motif
cell
epitop
cluster
score
consid
signific
immunogen
potenti
cell
epitop
cluster
contain
singl
frame
may
contain
sequenc
bind
least
four
differ
hla
allel
ivax
denot
featur
epibar
barlik
appear
epimatrix
report
peptid
contain
promiscu
bind
epitop
epibar
power
immunogen
exampl
includ
wellknown
cell
epitop
use
control
cell
assay
includ
influenza
hemagglutinin
figur
tetanu
toxin
observ
subject
expos
either
tularemia
vaccinia
respond
cell
epitop
pool
contain
promiscu
epitop
cluster
also
import
featur
selfprotein
often
involv
autoreact
cell
respons
wellknown
autoepitop
insulin
peptid
lqplalegslqkrgi
contain
signific
number
hla
dr
bind
motif
better
defin
immunogen
epitop
determin
epimatrix
cluster
score
cut
roughli
defin
number
signific
hla
bind
hit
divid
sequenc
length
featur
highli
immunogen
cluster
also
contrast
gener
trend
toward
deimmun
observ
protein
human
genom
found
complement
factor
subunit
higher
concentr
cell
epitop
suggest
may
perform
import
function
provid
noncogn
help
drive
humor
immun
respons
bind
antigen
taken
b
cell
peptid
locat
previous
defin
adjuv
region
complet
conserv
across
speci
mutat
singl
tcell
epitop
result
significantli
diminish
adjuv
activ
peptid
mice
support
hypothesi
epitop
activ
autoreact
thelper
cell
bridg
innat
adapt
immun
although
cell
possess
antiself
tcr
previous
thought
like
elimin
thymu
evid
emerg
show
antiselfimmun
respons
also
control
regulatori
cell
recogn
antigen
phenotyp
regulatori
cell
may
reinforc
figur
epimatrix
class
ii
analysi
analysi
influenza
hemagglutinin
sequenc
show
frame
contain
top
hit
top
hit
hla
dr
allel
featur
call
epibar
epitop
bar
featur
highli
immunogen
epitop
analysi
perform
use
hla
allel
repetit
reexposur
cognat
selfantigen
thu
human
immun
respons
new
antigen
shape
previou
experi
thymu
exposuredriven
reinforc
cours
immun
system
matur
observ
critic
antigen
human
pathogen
contain
cell
epitop
highli
conserv
selfantigen
postul
epitop
might
induc
ignor
activ
toler
antigen
upon
vaccin
result
immun
camouflag
retrospect
studi
determin
peptid
epitop
homolog
human
proteom
compat
exactli
match
mhc
bind
anchor
exactli
match
tcrface
contour
potenti
ignor
lack
immun
respons
induc
activ
toler
activ
cell
immunosuppress
bystand
assay
andor
exhibit
cell
surfac
marker
consist
cell
known
regulatori
cell
phenotyp
develop
janusmatrix
tool
identifi
humanlik
epitop
explor
impact
modifi
exclud
epitop
improv
antigen
vaccin
given
cell
epitop
janusmatrix
defin
amino
acid
contact
bind
mhc
molecul
also
identifi
amino
acid
make
contact
tcr
respond
cell
class
ii
restrict
epitop
posit
assum
make
contact
mhc
posit
assum
avail
tcr
figur
tcr
face
residu
class
epitop
vari
allel
allel
janusmatrix
algorithm
search
refer
databas
may
human
murin
organ
similar
epitop
take
consider
epitop
conserv
mhcface
agretop
tcrface
epitop
refer
sequenc
compat
perhap
sequenceident
agretop
ie
one
predict
epimatrix
bind
hla
input
peptid
exactli
match
tcr
contact
input
peptid
return
given
epimatrix
score
high
janusmatrix
homolog
score
suggest
cell
figur
janusmatrix
selflik
epitop
hla
ligand
two
face
hlabind
face
agretop
blue
residu
tcrinteract
face
epitop
green
residu
predict
ligand
ident
tcr
epitop
variant
hlabind
agretop
may
stimul
cross
reactiv
toler
treg
respons
provid
bind
hla
allel
recogn
epitop
may
exhibit
bia
toward
immun
toler
hypothesi
confirm
retrospect
prospect
studi
use
cutoff
two
crossconserv
hlaallelespecif
epitop
averag
length
sequenc
protein
self
three
protein
self
identifi
epitop
like
toler
activ
regulatori
cutoff
publish
first
prospect
test
tool
abl
identifi
cell
epitop
hepat
c
viru
high
janusmatrix
score
induc
regulatori
cell
vitro
suppress
immun
respons
peptid
specif
janusmatrix
identifi
promiscu
class
ii
epitop
nonstructur
hcv
protein
exhibit
homolog
tcr
face
hundr
human
proteomederiv
cell
epitop
induc
increas
treg
number
function
pbmc
cultur
deriv
hladivers
cohort
hcvinfect
patient
addit
found
similar
humanlik
epitop
emerg
influenza
abil
class
iirestrict
epitop
activ
modul
effector
cell
respons
correl
degre
crossconserv
tcrface
similar
epitop
human
proteom
defin
janusmatrix
epitop
activ
human
high
treg
suppress
effector
cell
respons
delet
treginduc
epitop
ha
produc
antigen
improv
ha
stimul
increas
activ
effector
cell
wild
type
vitro
stimul
greater
igg
titer
greater
b
cell
frequenc
mice
immun
wild
type
protein
human
mous
immun
biolog
area
discov
conserv
treginduc
epitop
tregitop
immunoglobulin
g
tcrface
pattern
found
sever
selfprotein
went
demonstr
tregitop
peptid
bind
multipl
mhc
class
ii
molecul
suppress
effector
cell
respons
codeliv
antigen
upregul
tregassoci
cytokin
chemokin
induc
antigenspecif
treg
vitro
vivo
consid
novel
idea
natur
regulatori
cell
engag
activ
peptid
epitop
possess
tcrface
motif
commonli
found
within
human
protein
gain
traction
concept
similar
janusmatrix
also
describ
research
group
also
recent
determin
cell
epitop
stimul
helper
cell
specif
human
subject
identifi
immunoinformat
analysi
predict
antigen
individu
epitop
whole
protein
util
patient
hla
type
perform
analysi
focu
predict
patientspecif
hla
allel
use
individu
cell
epitop
measur
item
tool
correct
crossconserv
epitop
present
hla
allel
use
janusmatrix
analysi
result
combin
two
tool
call
jitem
case
studi
use
new
combin
tool
provid
develop
epitop
predict
tool
swine
publish
method
use
develop
tool
tool
select
instead
human
hlaepitop
predict
tool
enabl
entir
ivax
toolkit
platform
appli
infecti
diseas
affect
swine
tool
current
appli
develop
univers
influenza
vaccin
pig
prepar
vaccin
eventu
emerg
african
swine
fever
asf
usa
address
anoth
import
issu
confront
hog
farmer
develop
immunoinformat
approach
match
exist
vaccin
circul
strain
help
farmer
pick
best
vaccin
individu
pork
farm
might
mitig
diseas
vaccineinduc
antibodi
protect
tool
call
epicc
cell
epitop
content
comparison
evalu
commerci
vaccin
compani
applic
wide
rang
swine
pathogen
includ
higher
epicc
score
thought
associ
greater
vaccin
protect
challeng
strain
first
studi
method
identifi
threshold
protect
may
determin
whether
vaccin
contain
suffici
cell
epitop
related
provid
crossconserv
immun
protect
challeng
strain
collabor
chri
eickhoff
dan
hoft
saint
loui
univers
identifi
cell
epitop
highli
conserv
divers
influenza
strain
shown
immunogen
human
express
genet
divers
mhc
proofofprincipl
studi
conduct
use
novel
vaccin
incorpor
newli
defin
cell
epitop
hla
transgen
mous
strain
respond
peptidemhc
combin
human
cell
vaccin
elicit
robust
cell
respons
provid
signific
protect
divers
influenza
challeng
provid
strong
support
celltarget
univers
influenza
vaccin
effort
develop
univers
influenza
vaccin
ongo
collabor
research
unit
state
saint
loui
univers
univers
georgia
europ
build
experi
rapid
fire
develop
vaccin
lassa
fever
epimatrix
janusmatrix
use
identifi
promiscu
class
ii
epitop
coxiella
burnetii
antigen
test
hla
bind
assay
screen
immunogen
transgen
mice
colleagu
vaccin
immunotherapi
center
vic
harvard
innatoss
oss
netherland
signific
epitopespecif
respons
found
peptid
predict
epitop
fisher
exact
pvalu
one
bound
vitro
vaccin
featur
epitop
develop
consortium
base
vaccin
immunotherapi
center
harvard
may
eventu
replac
exist
vaccin
qvax
andor
cell
epitop
may
use
develop
diagnost
reagent
helper
cell
central
develop
protect
immun
respons
p
falciparum
malaria
play
key
role
b
cell
activ
matur
process
work
ami
noe
vinayaka
kotraiah
leido
use
ivax
predict
analyz
hla
class
iirestrict
epitop
would
drive
humor
immun
respons
cognat
cell
help
provid
broad
popul
coverag
novel
p
falciparum
csp
protein
pfcsp
vaccin
cours
usaidfund
program
pfcsp
epitop
sequenc
variant
analyz
optim
sequenc
highest
crossstrain
coverag
select
next
stage
vaccin
develop
also
note
high
interstrain
variabl
csp
helper
epitop
tendenc
highli
conserv
csp
epitop
crossconserv
human
genom
antigen
highli
conserv
p
falciparum
bloodstag
antigen
recent
assess
phase
clinic
trial
control
human
malaria
infect
draper
colleagu
oxford
identifi
immunogen
nonhumanlik
epitop
use
ivax
also
analyz
immunogen
potenti
overlap
peptid
set
use
immun
recal
studi
use
epimatrix
clustim
janusmatrix
item
individu
cell
epitop
measur
well
adapt
janusmatrix
item
jitem
found
cell
respons
directli
correl
presenc
hladr
restrict
ligand
defin
use
epimatrix
absenc
humanlik
cell
epitop
peptid
induc
posit
respons
higher
item
jitem
score
p
respect
neg
peptid
class
ii
cell
epitop
vaccinia
viru
protein
identifi
elispot
assay
use
pbmc
smallpox
vaccine
research
studi
use
pbmc
clinic
studi
volunt
overlap
peptid
librari
four
vaccinia
membran
protein
known
induc
immun
respons
vaccin
individu
synthes
test
elispot
assay
use
pbmc
recent
smallpox
vaccin
recipi
cell
epitop
sequenc
retrospect
analyz
use
epimatrix
janusmatrix
found
peptid
identifi
cell
epitop
predict
bind
class
ii
hla
supertyp
allel
often
remaind
overlap
peptid
librari
p
peptid
identifi
class
ii
cell
epitop
lower
janusmatrix
human
homolog
score
remaind
overlap
peptid
librari
p
consist
identif
cell
epitop
describ
public
suggest
silico
bind
predict
correl
cell
respons
vitro
proof
concept
studi
recent
publish
crystal
love
colleagu
iowa
state
use
immunoinformat
tool
identifi
class
ii
cell
epitop
highli
conserv
seven
repres
strain
iav
us
swine
predict
bind
preval
swine
leukocyt
antigen
sla
allel
efficaci
intradermaldeliv
plasmid
dna
vaccin
compos
epitop
challeng
compar
intramuscular
commerci
inactiv
whole
viru
vaccin
heterolog
primeboost
approach
use
vaccin
recent
publish
result
suggest
heterolog
primeboost
approach
use
epitopedriven
dna
vaccin
follow
inactiv
vaccin
effect
homosubtyp
challeng
illustr
util
immunoinformat
approach
vaccin
design
epicc
tool
appli
success
describ
vaccin
protect
challeng
strain
influenza
use
prospect
develop
combin
vaccin
addit
pathogen
affect
swine
epicc
tool
recent
tool
integr
ivax
potenti
applic
includ
determin
influenza
viru
spillov
event
occur
transmiss
influenza
swine
human
predict
next
pandem
collabor
influenza
research
univers
georgia
athen
usa
janusmatrix
tool
may
also
relev
avoid
offtarget
effect
cell
therapi
tcrengin
cell
cartcr
cell
illustr
potenti
applic
janusmatrix
search
safeti
signal
cell
therapi
perform
entir
silico
approach
evalu
potenti
crossreact
engin
tcr
direct
peptid
present
hla
tumor
associ
signific
lethal
target
effect
janusmatrix
confirm
potenti
crossreact
tcr
face
similar
selfepitop
predict
present
hla
one
epitop
deriv
titin
protein
found
cardiac
muscl
offtarget
effect
tcrengin
cell
therapi
attribut
separ
report
potenti
target
titin
epitop
figur
concern
target
effect
engin
cell
cancer
vaccin
lead
develop
addit
algorithm
use
cell
epitop
comparison
evalu
cancer
vaccin
risk
figur
janusmatrix
analysi
cell
epitop
peptid
contain
ident
cell
face
residu
includ
variant
melanoma
associ
antigen
three
addit
human
protein
includ
human
titin
one
compon
cardiac
smooth
muscl
figur
show
hlaa
cell
epitop
evdpighvi
conserv
epitop
ident
hla
bind
restrict
slightli
differ
agretop
xspdxxvaqi
ident
tcr
face
residu
exxpixxxx
autolog
cell
transduc
gene
express
antitumorspecif
antigen
demonstr
signific
antitumor
activ
b
cell
malign
howev
immunogen
may
affect
efficaci
cell
studi
publish
cart
compani
juno
cellmedi
anticar
transgen
product
immun
respons
develop
cart
cell
infus
patient
cell
respons
limit
cart
cell
persist
increas
risk
relaps
risk
publish
studi
five
patient
develop
persist
leukemia
relaps
initi
infus
cart
receiv
second
infus
cart
cell
expans
persist
cart
cell
demonstr
antitumor
activ
five
patient
infus
follow
loss
cart
transduc
cell
popul
follow
studi
evalu
cell
respons
overlap
peptid
vitro
public
show
vh
vl
domain
cart
high
amount
class
epitop
content
use
proxi
report
patient
hla
type
epimatrix
analysi
show
agreement
predict
immunogen
sequenc
note
apart
scfv
compon
part
cart
structur
spacer
transmembran
domain
costimulatori
domain
signal
domain
sequenc
human
cell
epitop
rich
region
potenti
contribut
report
immunogen
cart
advanc
vaccin
design
use
comput
tool
measur
vaccin
efficaci
use
entir
vitro
system
vaccin
deliveri
use
broad
rang
flexibl
platform
move
vaccin
scienc
beyond
tradit
shake
bake
whole
kill
vaccin
yesteryear
forecast
tell
design
methodolog
futur
past
year
team
work
epivax
affili
academ
institut
develop
tool
design
vaccin
provid
vitro
vivo
evid
immunoinformat
tool
appli
vaccin
effect
protect
live
bacteri
viral
challeng
tool
also
use
improv
design
exist
vaccin
identifi
biomark
safeti
efficaci
effect
integr
silico
immunoinformat
tool
ex
vivoin
vitro
vivo
immun
system
technolog
across
entir
vaccin
develop
pipelin
enabl
develop
predict
assess
safeti
toxic
efficaci
qualiti
perform
vaccin
acceler
develop
safe
effect
immunotherapi
broad
rang
pathogen
speci
new
tool
describ
report
valid
retrospect
prospect
studi
describ
briefli
anticip
extend
public
result
elsewher
previou
public
shown
epimatrix
janusmatrix
algorithm
effici
identifi
put
cell
epitop
distinguish
like
inflammatori
peptid
potenti
regulatori
peptid
adapt
patient
hlaspecif
level
assess
result
confirm
combin
hlaspecif
epitop
content
self
improv
predict
immunogen
either
metric
alon
appli
tool
earli
stage
vaccin
design
antigen
select
engin
like
result
advanc
next
gener
vaccin
minim
essenti
compon
protect
deliv
without
offtarget
unintent
suppress
signal
deleteri
vaccin
efficaci
number
commerci
academ
team
activ
develop
new
vaccin
design
tool
also
contribut
innov
area
comput
vaccinolog
sever
group
exampl
develop
public
privat
comput
tool
predict
proteasom
cleavag
site
netchop
ivax
toolkit
current
use
epivax
inc
client
includ
commerci
firm
academ
collabor
develop
novel
vaccin
malaria
q
fever
burkholderia
commerci
develop
biodefens
contract
academ
group
engag
feder
fund
program
analyz
immun
respons
emergingreemerg
pathogen
influenza
univers
georgia
saint
loui
univers
pertussi
intravacc
innatoss
vic
cdc
even
recent
epivax
creat
seamless
pipelin
design
person
cancer
vaccin
capit
ivax
vaccin
develop
cell
immunolog
expertis
call
ancer
collabor
studi
carri
use
ivax
demonstr
import
comput
tool
vaccin
design
vaccin
efficaci
studi
addit
collabor
evalu
potenti
efficaci
exist
vaccin
newli
emerg
variant
predict
immun
respons
candid
antigen
newli
emerg
strain
infecti
diseas
design
novel
vaccin
enhanc
immunogen
acceler
pace
possibl
encourag
tradit
cancer
vaccin
base
tumor
associ
antigen
taa
part
fail
clinic
trial
evid
emerg
suggest
reason
fail
taa
broadli
recogn
self
immun
system
new
strategi
emerg
antigen
may
modifi
increas
immunogen
use
tool
one
describ
care
analysi
standard
taa
use
clinic
studi
reveal
presenc
put
treg
induc
epitop
may
respons
immunesuppress
effect
meanwhil
field
cancer
therapi
undergon
major
transform
less
decad
due
introduct
checkpoint
inhibitor
cpi
next
gener
sequenc
ng
new
emphasi
neoepitop
neoepitop
cell
epitop
contain
tumorspecif
nonsynonym
amino
acid
mutat
effect
distinguish
cancer
tumor
protein
normal
counterpart
neoepitop
repres
mutat
selfantigen
recogn
nonself
individu
immun
system
therefor
capabl
gener
potent
immunogen
clinic
respons
new
strategi
develop
person
vaccin
direct
immun
respons
patientspecif
cell
neoepitop
develop
unlik
taa
cancer
neoepitop
found
normal
tissu
also
unlik
taa
may
present
one
tumor
type
across
patient
vast
major
neoepitop
uniqu
patient
tumor
cost
sequenc
individu
tumor
genom
discov
neoepitop
drop
precipit
thousand
dollar
per
genom
combin
cpi
therapeut
vaccin
base
neoepitop
highli
like
improv
outcom
may
well
effect
singl
agent
certain
clinic
set
begin
epivax
develop
endtoend
immunoinformat
platform
separ
ivax
enabl
rapid
design
person
mutanomedirect
therapeut
peptid
cancer
vaccin
vaccin
target
multipl
antigen
specif
patient
tumor
encod
sever
class
class
ii
hla
restrict
neoepitop
proprietari
immunoinformat
pipelin
includ
epimatrix
janusmatrix
version
item
call
jitem
see
descript
call
ancer
exclus
licens
epivax
oncolog
inc
subsidiari
epivax
establish
epivax
oncolog
use
ancer
develop
individu
cancer
vaccin
screen
cancer
mutanom
identifi
tumorspecif
neoepitop
use
epimatrix
filter
neoepitop
may
tolerogen
use
janusmatrix
rank
remain
neoantigen
accord
optim
immunogen
profil
number
compani
develop
tool
identifi
neoepitop
rapidli
expand
access
high
throughput
commercialgrad
valid
tool
incorpor
consider
rule
selftoler
critic
import
design
effect
safer
vaccin
cancer
immunotherapi
develop
ivax
toolkit
ancer
pipelin
imagin
nottodist
futur
mani
immunotherapi
cancer
also
infecti
diseas
autoimmun
diseas
allergi
design
administ
within
week
diagnosi
also
anticip
broader
applic
tool
pathogen
afflict
food
anim
includ
fish
companion
anim
quickli
addit
epitop
predict
capac
ad
twenti
year
comput
develop
collabor
valid
studi
built
strong
foundat
comput
vaccinolog
bright
futur
enorm
potenti
improv
human
anim
health
dataset
analyz
articl
publicli
avail
part
ongo
research
publish
later
date
request
access
dataset
direct
william
martin
martinb
epivaxcom
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
effort
karen
nelson
expert
editori
assist
grate
acknowledg
onlin
version
ivax
toolkit
develop
wm
expert
program
team
epivax
support
subcontract
epivax
nih
grant
triad
pi
ad
avail
leas
commerci
firm
use
academ
collabor
grantfund
collabor
agreement
artist
contribut
geneviev
degroot
figur
grate
acknowledg
